  Protein-ligand interactions (PLIs) are fundamental to biochemical research
and their identification is crucial for estimating biophysical and biochemical
properties for rational therapeutic design. Currently, experimental
characterization of these properties is the most accurate method, however, this
is very time-consuming and labor-intensive. A number of computational methods
have been developed in this context but most of the existing PLI prediction
heavily depends on 2D protein sequence data. Here, we present a novel parallel
graph neural network (GNN) to integrate knowledge representation and reasoning
for PLI prediction to perform deep learning guided by expert knowledge and
informed by 3D structural data. We develop two distinct GNN architectures, GNNF
is the base implementation that employs distinct featurization to enhance
domain-awareness, while GNNP is a novel implementation that can predict with no
prior knowledge of the intermolecular interactions. The comprehensive
evaluation demonstrated that GNN can successfully capture the binary
interactions between ligand and proteins 3D structure with 0.979 test accuracy
for GNNF and 0.958 for GNNP for predicting activity of a protein-ligand
complex. These models are further adapted for regression tasks to predict
experimental binding affinities and pIC50 is crucial for drugs potency and
efficacy. We achieve a Pearson correlation coefficient of 0.66 and 0.65 on
experimental affinity and 0.50 and 0.51 on pIC50 with GNNF and GNNP,
respectively, outperforming similar 2D sequence-based models. Our method can
serve as an interpretable and explainable artificial intelligence (AI) tool for
predicted activity, potency, and biophysical properties of lead candidates. To
this end, we show the utility of GNNP on SARS-Cov-2 protein targets by
screening a large compound library and comparing our prediction with the
experimentally measured data.
